Plasmid manufacturing is evolving. Learn how innovations like automation, continuous processing, and AI are addressing challenges and setting new industry standards at Anemocyte.”

Plasmids are the unsung heroes of gene therapy, driving breakthroughs from CRISPR technology to mRNA vaccines. Explore Anemocyte’s pivotal role in advancing next-generation therapies.

The year 2024 has been a transformative period for biotechnology and gene therapy, with groundbreaking developments improving patient outcomes and expanding access to life-saving treatments.

RNA-based technologies include messenger RNA (mRNA), RNA interference (RNAi), and the emerging circular RNA (circRNA), each offering a unique pathway to address genetic and protein-level diseases effectively.

Therapeutic innovations are as diverse as the challenges they address—ranging from gene and cell therapies to mRNA-based treatments and next-generation biologics.

mRNA technology has emerged as a transformative force in the biopharmaceutical industry, enabling groundbreaking therapies and vaccines, including those for COVID-19.